Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma

IF 2.5 4区医学 Q3 IMMUNOLOGY

Immunobiology Pub Date : 2025-07-01 DOI:10.1016/j.imbio.2025.153096

Yuqi Wang , Zhongxin Zheng , Qiaoxi Kang , Linjing Cai , Shanshan Zhang , Huan Chen , Youhai Yuan , Hanzhen Zhang , Xiaolei Wei , Ru Feng , Yongqiang Wei

{"title":"Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma","authors":"Yuqi Wang , Zhongxin Zheng , Qiaoxi Kang , Linjing Cai , Shanshan Zhang , Huan Chen , Youhai Yuan , Hanzhen Zhang , Xiaolei Wei , Ru Feng , Yongqiang Wei","doi":"10.1016/j.imbio.2025.153096","DOIUrl":null,"url":null,"abstract":"<div><div>Previous evidence suggested that B lymphocytes may be involved in the progression and prognosis of multiple myeloma (MM). However, the prognostic value of peripheral B lymphocyte counts on MM before and after treatment in the novel agent era was rarely reported. Herein, we conducted a retrospective study in our center to detect peripheral B lymphocyte counts by flow cytometry in 110 patients with MM and explore the relation with survival. The B lymphocyte count was significantly lower in MM patients than healthy controls (<em>p</em> < 0.005). The cutoff value of B lymphocyte count at diagnosis was 49/μl in MM and 94 patients were divided into in high B lymphocyte group. Patients with low B lymphocyte count had a significant shorter progression-free survival (PFS) (<em>p</em> = 0.025) and a trend of unfavorable overall survival (OS) (<em>p</em> = 0.053) at diagnosis and after 4 cycles' induction treatments. Furthermore, Multivariate analysis showed that low B lymphocyte count at diagnosis independent of ISS stage was a significantly inferior marker for predicting PFS (<em>p</em> = 0.027, hazard ratio(HR) 2.281, 95 % confidence interval (CI) 1.098–4.741) and a trend for OS (<em>p</em> = 0.083, HR 2.394, 95 % CI 0.896–6.160). In summary, these results suggested the low B lymphocyte count was associated with poor outcome in MM patients at diagnosis and after treatment in the novel agent era.</div></div>","PeriodicalId":13270,"journal":{"name":"Immunobiology","volume":"230 4","pages":"Article 153096"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunobiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S017129852500230X","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Previous evidence suggested that B lymphocytes may be involved in the progression and prognosis of multiple myeloma (MM). However, the prognostic value of peripheral B lymphocyte counts on MM before and after treatment in the novel agent era was rarely reported. Herein, we conducted a retrospective study in our center to detect peripheral B lymphocyte counts by flow cytometry in 110 patients with MM and explore the relation with survival. The B lymphocyte count was significantly lower in MM patients than healthy controls (p < 0.005). The cutoff value of B lymphocyte count at diagnosis was 49/μl in MM and 94 patients were divided into in high B lymphocyte group. Patients with low B lymphocyte count had a significant shorter progression-free survival (PFS) (p = 0.025) and a trend of unfavorable overall survival (OS) (p = 0.053) at diagnosis and after 4 cycles' induction treatments. Furthermore, Multivariate analysis showed that low B lymphocyte count at diagnosis independent of ISS stage was a significantly inferior marker for predicting PFS (p = 0.027, hazard ratio(HR) 2.281, 95 % confidence interval (CI) 1.098–4.741) and a trend for OS (p = 0.083, HR 2.394, 95 % CI 0.896–6.160). In summary, these results suggested the low B lymphocyte count was associated with poor outcome in MM patients at diagnosis and after treatment in the novel agent era.

查看原文本刊更多论文

外周血B淋巴细胞计数低预示多发性骨髓瘤患者预后不良

已有证据表明B淋巴细胞可能参与多发性骨髓瘤（MM）的进展和预后。然而，在新型药物时代，外周血B淋巴细胞计数对MM治疗前后的预后价值很少报道。为此，我们在本中心进行回顾性研究，用流式细胞术检测110例MM患者外周血B淋巴细胞计数，并探讨其与生存率的关系。MM患者B淋巴细胞计数明显低于健康对照组(p <；0.005)。MM诊断时B淋巴细胞计数临界值为49/μl， 94例患者分为高B淋巴细胞组。B淋巴细胞计数低的患者在诊断时和诱导治疗4个周期后无进展生存期（PFS）显著缩短（p = 0.025），总生存期（OS）有不利趋势（p = 0.053）。此外，多因素分析显示，诊断时B淋巴细胞计数低与ISS分期无关，是预测PFS （p = 0.027，风险比（HR） 2.281, 95%可信区间（CI） 1.098 ~ 4.741）和OS （p = 0.083，风险比（HR） 2.394, 95%可信区间（CI） 0.896 ~ 6.160）的较差指标。总之，这些结果表明，在新型药物时代，低B淋巴细胞计数与MM患者诊断时和治疗后的不良预后有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunobiology 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

108

审稿时长

55 days

期刊介绍： Immunobiology is a peer-reviewed journal that publishes highly innovative research approaches for a wide range of immunological subjects, including • Innate Immunity, • Adaptive Immunity, • Complement Biology, • Macrophage and Dendritic Cell Biology, • Parasite Immunology, • Tumour Immunology, • Clinical Immunology, • Immunogenetics, • Immunotherapy and • Immunopathology of infectious, allergic and autoimmune disease.